MemoryLinc® ncRNA multiplex RT-qPCR IVD assay kit
1 / 2Pages

ncRNA multiplex RT-qPCR IVD assay kit the diagnosis of Alzheimer's Disease First in class blood test to diagnose Alzheimer’s Disease (AD) ncRNA signature quanti- fication with RT-qPCR test Crafted in a high-quality setting The MemoryLinc® ncRNA multiplex RT-qPCR IVD assay kit is a reverse transcription (RT) quantitative polymerase chain reaction (qPCR) test for the in vitro quantitative determination of non-coding RNA (ncRNA) signature in plasma-EDA (human) to aid in the diagnosis of Alzheimer's Disease (AD) in conjunction with clinical findings and the results of laboratory testing. Fig 1. MemoryLinc® simplified workflow The purpose of the MemoryLinc® ncRNA multiplex RT-qPCR IVD assay kit is to evaluate plasma samples and must be utilized in conjunction with the Quantstudio 5 Dx real-time PCR system. It is designed for implementation by qualified clinical laboratory personnel who have received specific instruction and training in RT-PCR techniques and in vitro diagnostic procedures. Amoneta Diagnostics | 17, Rue du Fort, 68330 Huningue, France | +33 3 89 91 13 20 | contact@amoneta-diagnostics.

Applications and performance The MemoryLinc® panel leads to highly reproducible results that can be used to diagnose AD at an early stage. Fig 2. ROC curve for miAD vs HC comparison with Lasso model with and without APOE genotypes The performance of signature based on a subset of ncRNAs detected in MemoryLinc® panel have been successfully applied to diagnose AD patients compared to healthy control. Our company Amoneta Diagnostics, subsidiary of Firalis, is a biotech company committed to advancing the understanding and diagnosis of NDs by leveraging a range of cutting-edge technology and...